Evidence map›Paper›PMID 39073853›Full record

ArticleJournal of medicinal chemistry2024

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor.

Xianglin Huang, Anna Chorianopoulou, Panagoula Kalkounou, Maria Georgiou, Athanasios Pousias, Amy Davies, Abigail Pearce, Matthew Harris, George Lambrinidis, Panagiotis Marakos and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xianglin HuangDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.
Anna ChorianopoulouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.ORCID 0009-0004-4849-4633
Panagoula KalkounouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Maria GeorgiouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Athanasios PousiasLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Amy DaviesDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.
Abigail PearceDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.ORCID 0000-0001-9845-0541
Matthew HarrisDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.
George LambrinidisLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.ORCID 0000-0002-2820-9338
Panagiotis MarakosLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Nicole PouliLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Antonios KolocourisLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.ORCID 0000-0001-6110-1903
Nikolaos LougiakisLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou 15771, Athens, Greece.
Graham LaddsDepartment of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, U.K.ORCID 0000-0001-7320-9612

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antagonism of the human adenosine A

Indexed as

Adenosine A3 Receptor AntagonistsReceptor, Adenosine A3AnimalsCell Line, TumorCHO CellsCricetulusHeterocyclic CompoundsHumansMolecular Dynamics SimulationRatsStructure-Activity RelationshipAdenosine A3 Receptor AntagonistsHeterocyclic CompoundsReceptor, Adenosine A3

Identifiers

PMID39073853
PMCPMC11320584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.